1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,200 | 4,340 | 23:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.10. | MaaT Pharma stock jumps 11% after DSMB clears Phase 2b trial to continue | 5 | Investing.com | ||
| 07.10. | MaaT Pharma's MaaT033 For Allo-HSCT Patients Clears Second DSMB Safety Review In Phase 2b Trial | 2 | RTTNews | ||
| 07.10. | MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT | 232 | Business Wire | The DSMB conducted an unblinded safety review of data from the first 120 enrolled patients and identified no safety concerns and no excessive mortality related to MaaT033 as of today. The... ► Artikel lesen | |
| MAAT PHARMA Aktie jetzt für 0€ handeln | |||||
| 17.09. | MaaT Pharma Publishes Its Half Year 2025 Results and Provides a Business Update | 423 | Business Wire | Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results showed a 62% gastrointestinal overall response rate at Day 28 and 1-year expected Overall... ► Artikel lesen | |
| 30.07. | MaaT Pharma: €37.5 Million EIB Loan Secured To Advance Cancer Therapies | 3 | pulse2.com | ||
| 28.07. | MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology | 489 | Business Wire | Tranche-based financing to support clinical development for the Company's late-stage assets in hemato-oncology including Xervyteg currently under review for potential approval by the EMA and MaaT033... ► Artikel lesen | |
| 24.07. | MaaT Pharma: Half-year Report to the Liquidity Contract With Kepler Cheuvreux | 278 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 07.07. | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 289 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority
(AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 02.07. | MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg in acute Graft-versus Host Disease in Europe | 491 | Business Wire | MaaT Pharma and Clinigen signed exclusive long-term licensing and distribution agreement and commercial supply agreement for Xervyteg(MaaT013), its first in class treatment proposed for patients... ► Artikel lesen | |
| 24.06. | MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting | 343 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies(MET) dedicated to enhancing... ► Artikel lesen | |
| 19.06. | MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025 | 477 | Business Wire | Marketing Authorization application of Xervyteg (MaaT013) in acute graft-versus-host-disease submitted to the European Medicines Agency (EMA) in June 2025
MAA could be expected in H2 2026... ► Artikel lesen | |
| 13.06. | MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg at the EHA Congress Validating High Efficacy Observed in Pivotal ARES Study in Acute Graft-versus-Host Disease | 404 | Business Wire | Oral presentation highlights updated data in Early Access Program (EAP) for 173 patients with acute Graft-vs-Host Disease (aGvHD) treated with Xervyteg
Independent dataset from EAP reinforces... ► Artikel lesen | |
| 02.06. | MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg (MaaT013) in Acute Graft-versus-Host Disease | 448 | Business Wire | MaaT Pharma submitted today a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its product candidate MaaT013, under the registered brand name of Xervyteg
Xervyteghas... ► Artikel lesen | |
| 14.05. | MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress | 344 | Business Wire | Oral presentation will highlight updated data in Early Access Program (EAP) for 173 patients with acute Graft-vs-Host Disease (aGvHD) treated with MaaT013.
Poster presentation selected... ► Artikel lesen | |
| 14.05. | MaaT Pharma to Hold Annual General Meeting on June 20, 2025 | 418 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 13.05. | MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025 | 389 | Business Wire | Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results showed a 62% gastrointestinal overall response rate at Day 28 and 1-year expected Overall... ► Artikel lesen | |
| 12.05. | MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS) | 408 | Business Wire | Regulatory News:
MaaT Pharma(EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 29.04. | AACR 2025: MaaT Pharma, the gut microbiome, and immuno-oncology | - | pharmaphorum | ||
| 28.04. | MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034 | 355 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 14.04. | Availability of MaaT Pharma's 2024 Universal Registration Document (URD) | 328 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HEIDELBERG PHARMA | 3,160 | +0,96 % | EQS-News: Heidelberg Pharma AG: Heidelberg Pharma erhält Fast-Track-Status von der US FDA für seinen führenden ADC-Kandidaten HDP-101 zur Behandlung des multiplen Myeloms | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Sonstiges
Heidelberg Pharma erhält Fast-Track-Status von der US FDA für seinen führenden ADC-Kandidaten HDP-101 zur Behandlung... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,570 | +1,22 % | Viking Therapeutics-Aktie: Die spannendste Adipositas-Wette? | Nach unserem letzten Kauftipp Ende vergangenen Monats hat die Aktie von Viking Therapeutics wieder Fahrt aufgenommen und konnte über 20% zulegen. Vor den kommenden Quartalszahlen kocht die Spannung... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 22,000 | -1,26 % | Intellia (NTLA) Soars 13% to Fresh High | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,724 | +2,95 % | PacBio to Report Third Quarter 2025 Financial Results on November 5, 2025 | ||
| ATAI LIFE SCIENCES | 5,050 | +5,80 % | Analyst Expectations For ATAI Life Sciences' Future | ||
| BIOMERIEUX | 113,10 | -0,70 % | Dividendenbekanntmachungen (09.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALLSTATE CORPORATION US0200021014 1 USD 0,8776 EUR ALPHABET INC CL A US02079K3059 0,21 USD 0,1842 EUR ALPHABET INC CL C US02079K1079 0... ► Artikel lesen | |
| AC IMMUNE | 2,680 | +10,52 % | AC Immune reports first TDP-43 PET tracer characterization in study | ||
| BIO GREEN MED SOLUTION | 1,740 | -17,49 % | Bio Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd. | KUALA LUMPUR, Malaysia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (Nasdaq: BGMS, Nasdaq: BGMSP) ("Bio Green Med" or the "Company"), a company engaged in diversified industries... ► Artikel lesen | |
| CYBIN | 5,400 | +4,85 % | Cybin gibt Update zur Neuropsychiatrie-Plattform und bevorstehenden klinischen Meilensteinen | - Erfolgreich abgeschlossene Aufnahme von 36 Teilnehmern in die Phase-2-Studie zu CYB004, dem DMT-Programm (deuteriertes Dimethyltryptamin, "DMT") des Unternehmens zur
Behandlung der... ► Artikel lesen | |
| ADICET BIO | 0,769 | +3,92 % | MaxCyte, Inc: MaxCyte Signs Platform License Agreement with Adicet Bio | MaxCyte's Flow Electroporation® technology and ExPERT platform to support development of Adicet's gamma delta T cell therapy gene edited programs ROCKVILLE, Md., Aug. 04, 2025 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| GENUS | 29,200 | 0,00 % | Genus: Underlying Group Trading In-line With Expectations | LONDON (dpa-AFX) - Genus (GNS.L) issued trading update for fiscal year ended 30 June 2025. The Group said it recorded strong underlying Group trading in-line with expectations. As a result of... ► Artikel lesen | |
| ANAPTYSBIO | 30,200 | +2,72 % | AnaptysBio, Inc.: Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025 | SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that... ► Artikel lesen | |
| ABIONYX PHARMA | 4,010 | +6,23 % | ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis | A Global Turning Point for Critical Care Medicine
Regulatory News:
ABIONYX Pharma, (FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 1,010 | +1,51 % | XTL Biopharmaceuticals: CEO Noam Band rückt in den Verwaltungsrat auf | ||
| AKESO | 12,500 | +0,81 % | CICC Cuts AKESO's TP to HKD184; Rating Kept Outperform |
Das Unternehmen MAAT PHARMA SA kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 4,280 Euro und damit -0,70 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAAT PHARMA SA finden Sie auf Wallstreet Online.